A growing team of groundbreaking scientists around the world are now sharing their lab notebooks online
His6-FLAG-ABHD233-425 (PBC042 A11) Purification: Nickel & Size Exclusion Chromatography This post is also available at: Recombinant Expression and Purification of ABHD2 from E. coli | Zenodo DOI: 10.5281/zenodo.7696914 For relevant background please see relevant page: A promising target for non-hormonal contraception – The a/b Hydrolase Domain 2 | Zenodo Expression of ABHD2 For each 1.8 Read More …
My goal is to look for strategies and chemical starting points to inhibit viral helicases, with a primary focus on the SARS-CoV-2 helicase NSP13. In a previous post, I showed that a binding pocket in the human helicase SNRNP200 exploited by an allosteric inhibitor (PDB code 5URK) was absent in SARS-CoV-2. Here, I analyze another Read More …
To develop novel inhibitors for viruses with pandemic potential, we have turned our attention towards targeting their helicases due to their high sequence conservation and essential role in viral replication (Newman et al., Nature communications, 2021). SARS-CoV-2 is especially interesting as its helicase, NSP13, was determined to have druggable binding pockets, some of which are Read More …
This is a summary of a detailed analysis that is available here. Helicases are motor proteins that separate double helices through the hydrolysis of ATP analogues (Fairman-Williams et al., Current Opinion in Structural Biology, 2010). They constitute one of the largest enzyme groups, as multiple varieties of helicases are present in all forms of cellular Read More …
SARS-CoV-2 Helicase (NSP13) as a drug target: The pandemic caused by SARS-CoV-2 is not over yet but instead has transformed into a chronic illness. So far, the expedited effort on drug development produced Mpro targeting drugs (Paxlovid) and repurposed RdRp inhibitor Molnupiravir. For effective long-term treatment, we intend to discover complementary antivirals targeting replication machinery Read More …
In searching for novel drugs that will treat future viral pandemics, the AViDD program has prioritized viral proteases, helicases, and RNA-dependant RNA polymerases (RdRps) as key targets in the fight to control viral replication. At the time of writing, several drugs are either in the clinic or on the market for SARS-CoV-2 proteases and RdRps, Read More …
Introduction: The outbreak of COVID-19 demonstrated the scarcity of drugs in the development pipeline to decrease the mortality and morbidity caused by the new pathogenic SARS-CoV-2 virus. Despite the improved diagnosis and screening processes, broad directly-acting anticoronavirus drugs were not immediately available to treat viral infections. In response to this health threat, the Rapidly Emerging Read More …
Introduction to Probe my pathway (PMP): accessible at apps.thesgc.org/pmp/ Despite the sequence of the whole human genome 20 years ago, our knowledge of the human proteome remains fragmented. While ~65% of the human proteome has been investigated in varying degrees, about 35% of the human proteome remains uncharacterized (the ‘dark proteome’). A key obstacle Read More …
